ME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome
ME/CFS is the illness where a good day is the dangerous one. Do a little too much, feel fine, then crash a day or two later for days or weeks. It has been called hysteria, "yuppie flu" and a "new clinical entity", and none of the labels helped. The biology is real but unfinished, the trials are mostly sobering, and the single most useful thing a clinician can do costs nothing: ask what happens the day after exertion.
At a glance
- What it is: a chronic multisystem illness defined by post-exertional malaise (PEM), with unrefreshing sleep, cognitive impairment and often orthostatic intolerance, and at least a 50% fall in pre-illness activity in most definitions.
- Hallmark: PEM is symptoms worsening after physical, cognitive or emotional effort, often 12β48 h later, lasting days or weeks (NICE 2021). After a 2-day exercise test, recovery took a mean 12.7 days vs 2.1 in sedentary controls (Moore 2023).
- Common and missed: 1.3% of US adults (NHIS 2021β22); 84β91% undiagnosed (IOM 2015). Australia: 0.2β1.0% (NHMRC 2019); Emerge Australia estimates about 250,000 people.
- Often post-infectious: 11% met CFS criteria 6 months after EBV, Q fever or Ross River virus (Dubbo cohort). After COVID-19, 4.5% met criteria vs 0.6% of the uninfected (RECOVER 2025).
- Management: diagnosis, energy management (pacing), symptom treatment and support. No drug cures it. NICE 2021: don't offer graded exercise therapy (GET); CBT only as supportive, not curative.
Biggest take-home: ask about PEM ("what happens the day after you push yourself?"). It makes the diagnosis, and it's why "just do a bit more each week" can backfire.
For patients: ME/CFS, Long COVID and POTS. For clinicians: the POTS deep dive.
Definition
- IOM 2015 (proposed name SEID, systemic exertion intolerance disease): 3 required: substantial reduction in activity for >6 months with new fatigue not relieved by rest; PEM; unrefreshing sleep. Plus cognitive impairment or orthostatic intolerance. Symptoms present at least half the time at moderate or greater intensity.
- NICE NG206 (2021): suspect when debilitating fatigue, PEM, unrefreshing sleep and cognitive difficulties all persist β₯6 weeks in adults (β₯4 weeks in children); diagnose at 3 months.
- Canadian Consensus Criteria (2003): PEM mandatory; 6 months in adults, 3 in children.
- International Consensus Criteria (2011): "post-exertional neuroimmune exhaustion" compulsory, plus neurological, immune/GI/GU and energy-metabolism symptoms; no 6-month wait.
- Fukuda (CDC 1994): 6 months of fatigue plus 4 of 8 symptoms; PEM optional. Oxford criteria (fatigue alone) were used in PACE. Trials using these may include people without PEM.
- Severity (ICC): mild (about 50% less activity), moderate (mostly housebound), severe (mostly bedbound), very severe (bedbound and dependent for care).
History
- 1948, Akureyri, Iceland: BjΓΆrn Sigurdsson and colleagues described "a disease epidemic in Iceland simulating poliomyelitis".
- 1949β51, Adelaide: R.A. Pellew reported an outbreak in South Australia (Med J Aust 1951), with follow-up in 1955.
- 1955, Royal Free Hospital, London: about 292 staff fell ill but only 12 inpatients; the hospital closed from 25 July to early October. Melvin Ramsay studied it; a 1956 Lancet editorial proposed "benign myalgic encephalomyelitis".
- 1970, McEvedy and Beard: two BMJ papers recast the Royal Free outbreak as "epidemic hysteria". Microbiologist Betty Dowsett, working with Ramsay, pursued enteroviral links and reviewed about 400 patients.
- 1984β85, Incline Village, Lake Tahoe: about 90 patients diagnosed with "chronic EBV" by a two-doctor practice (MMWR 1986). In 1988 Holmes and the CDC renamed it "chronic fatigue syndrome".
- 2003β2011, Canada and beyond: Bruce Carruthers led the Canadian and International Consensus Criteria; the 2011 panel spanned 13 countries, including Nancy Klimas (Miami) and Rosamund Vallings (New Zealand).
- 2014, Osaka: Nakatomi, Yasuyoshi Watanabe and colleagues reported PET evidence of neuroinflammation (n=9).
- 2015β2025: IOM report (2015), NICE NG206 (2021), the NIH deep-phenotyping study (2024) and DecodeME's first genome-wide results (2025).
Pathophysiology
Many signals across immune, autonomic, metabolic and brain systems; no unifying mechanism and no validated biomarker. Treat each finding below as a lead, not a test.
- PEM on testing: on a repeat cardiopulmonary exercise test (CPET) 24 h later, workload at ventilatory threshold fell 21 W more than in controls (meta-analysis, 4 studies; Franklin and Graham 2022). Largest study: day-2 decline in 84 ME/CFS vs none in 71 controls (Keller 2024). Against: no day-2 change in 58 vs 25 (Mancini 2026).
- Brain blood flow: on tilt, cerebral blood flow fell 26% in 429 ME/CFS vs 7% in 44 controls, including those with normal heart rate and blood pressure; 90% had an abnormal fall (van Campen 2020). The NIH study found no tilt differences.
- Immune: NK cell cytotoxicity about half of controls (meta-analysis, 28 papers, Hedges' g 0.96, high heterogeneity; Baraniuk 2024). CD8 T-cell exhaustion signatures (Iu 2024). More PD-1+ CD8 T cells in CSF (Walitt 2024).
- Autoantibodies: raised Ξ²2-adrenergic, M3 and M4 receptor antibodies in 29.5% of 268 patients (Loebel 2016). Doubt: the same commercial assay found no difference in POTS, with 98% of patients and 100% of controls "positive" for Ξ±1 (Hall 2022). B-cell depletion failed (RituxME).
- Metabolism: a "hypometabolic" profile, 80% of discriminating metabolites decreased (Naviaux 2016, n=84); amino acid pattern suggesting impaired pyruvate dehydrogenase (Fluge 2016, 200 vs 102). BioMapAI multi-omics in 249 people (Xiong 2025) linked microbiome, metabolome and immune changes.
- Brain: NIH deep phenotyping (17 post-infectious ME/CFS vs 21 controls) found lower CSF catechols, reduced right temporal-parietal junction activation and an "effort preference" difference; critics argue that last finding reflects limited capacity, not choice (Kirvin-Quamme 2025). PET neuroinflammation (Nakatomi 2014) didn't replicate (Raijmakers 2022).
- Genetics: DecodeME (15,579 cases vs 259,909 controls) found 8 loci, near genes such as BTN2A2, OLFM4 and RABGAP1L (infection response) and CA10 (chronic pain). No shared causal variants with depression or anxiety at the loci tested. Still a preprint.
Epidemiology
- Global: meta-analytic prevalence 0.68% (45 studies, about 1.09 million people); 0.89% by Fukuda criteria. Interview-based 1.14% vs physician-diagnosed 0.09% (Lim 2020).
- USA: 1.3% of adults (women 1.7%, men 0.9%); about 2% at ages 50β69; higher in non-metro areas (1.9%) and below the poverty line (2.0%) (NCHS 2023).
- Sex ratio: about 1.5β2:1 female in population surveys; about 3:1 in Norwegian registry incidence (IRR 3.2) and clinic samples. "3:1" fits clinics more than communities.
- Age: bimodal onset, peaks at 10β19 and 30β39 years (Norway, n=5,809). Children: 0.55% (Lim 2020).
- Australia: 0.2β1.0%, about 48,000β240,000 people, on old data (NHMRC 2019). GP records (MedicineInsight 2015β19) captured only about 0.1%, peak 50β59, women about 2.5 times men; authors call it an underestimate.
- Severity: at least 1 in 4 house- or bedbound at some point (IOM 2015; clinic and survey samples).
- Cost: about A$14.5 billion a year in Australia, mostly lost income (Close 2020; modelled from n=85).
Causes and risk factors
- Infection: post-infective fatigue syndrome in 12% at 6 months and 9% at 12 months after EBV, Q fever or Ross River virus, with similar rates across all three; the best predictor was severity of the acute illness (Dubbo, Hickie 2006, n=253).
- Adolescent glandular fever: 13% met CFS criteria at 6 months, 7% at 12, 4% at 24; all 13 cases at 24 months were female (Katz 2009, n=301).
- COVID-19: RECOVER-Adult: 4.5% (531/11,785) vs 0.6% of uninfected met IOM criteria; HR 4.93 (Vernon 2025). In a selected Berlin clinic sample, 19 of 42 with post-COVID exertion intolerance met CCC (Kedor 2022).
- Influenza: 2009 H1N1 infection doubled ME/CFS risk in Norway (HR 2.04); vaccination did not raise it (HR 0.97) (Magnus 2015).
- Family: relative risk 2.70 in first-degree relatives (Utah genealogy, Albright 2011).
- Overlap (mostly selected, cross-sectional): POTS 28% on tilt (van Campen 2020); IBS 37% pooled but IΒ² 99.5% (Rajabi 2026); self-assessed hypermobility 15.5% (Mudie 2024); mast cell activation up to 25% by largely self-reported criteria (Rohrhofer 2025). Fibromyalgia overlap is common clinically; reliable figures are scarce. Treat MCAS and hEDS links as unproven.
Preventable factors
- No proven primary prevention. Avoiding the triggering infections is the only plausible lever; influenza vaccination didn't raise risk while infection doubled it (Magnus 2015).
- Prevent worsening: NICE advises against fixed incremental increases in activity. In self-selected surveys, 54β74% reported getting worse with GET (Geraghty 2019; survey data, not trials).
- Prevent delay: suspect at 6 weeks, diagnose at 3 months (NICE), so people get energy-management advice early.
- Prevent severe harm: watch nutrition, hydration and complications of immobility in severe disease. A 2024 UK inquest found Maeve Boothby O'Neill died of malnutrition resulting from severe ME; the coroner reported no specialist beds for severe ME in England.
- Prevent misdiagnosis: do the baseline tests and look for treatable mimics, and don't label every fatigue ME/CFS without PEM.
Diagnosis essentials
- Ask about PEM directly: "What happens when you push to do things that are now hard?", "How much does it take to make you feel ill?", "How long until you feel better?", "What do you now avoid?" (CDC). Ask about delay: many crash hours or a day later, but only 11% report a consistent delay of β₯24 h (Chu 2018, n=150).
- Structured tool: the DSQ-PEM items (NIH/CDC common data elements) classified ME/CFS correctly 81.7% of the time (Cotler 2018).
- Criteria: NICE 2021 or IOM 2015 in practice; ICC or CCC in research. Record severity (mild to very severe).
- Baseline tests (NICE): urinalysis, FBC, U&E, LFT, TFT, ESR or plasma viscosity, CRP, calcium and phosphate, HbA1c, ferritin, coeliac serology, CK. By judgement: vitamin D, B12, folate, infection serology, 9am cortisol.
- Orthostatic intolerance: a passive stand or tilt test documents POTS or orthostatic hypotension (US Clinician Coalition, Bateman 2021).
- Mimics to consider: anaemia, thyroid and adrenal disease, coeliac disease, sleep apnoea, depression (anhedonia rather than PEM), inflammatory and neurological disease, medicines. Depression can coexist; it doesn't explain PEM.
- Don't need a 2-day CPET: it isn't required for diagnosis and can trigger weeks of PEM (mean recovery 12.7 days; Moore 2023).
Current treatment
No disease-modifying treatment. The evidence for everything below is low or very low certainty.
Energy management and rehabilitation
- Pacing: staying within the energy envelope, planning rest, using diaries, activity trackers or heart-rate monitors (NICE 1.11). No RCT shows pacing is efficacious; PACE's adaptive pacing arm did no better than usual care (fatigue β0.7 points, p=0.38). In self-selected surveys, 44β82% reported benefit (Geraghty 2019).
- PACE trial (White 2011, n=641, Oxford criteria): at 52 weeks vs specialist care, Chalder fatigue β3.4 (CBT) and β3.2 (GET); SF-36 physical function +7.1 and +9.4. Unblinded, self-rated outcomes.
- PACE reanalysis (Wilshire 2018): with protocol-specified definitions, "recovery" was 7% (CBT), 4% (GET), 3% (control), not significant; the published 2013 definition (22% vs 7%) let physical function fall below the trial's entry threshold.
- Cochrane (Larun 2019, 8 RCTs, n=1,518): exercise reduced fatigue at end of treatment (SMD β0.66, moderate certainty); long-term and harm outcomes very low certainty; all trials used Fukuda or Oxford criteria. The planned update was discontinued in December 2024.
- NICE 2021: GET and CBT evidence rated mostly low or very low. Don't offer GET, fixed incremental exercise or programmes based on deconditioning theories; CBT may help people manage symptoms "but it is not curative". Physical activity only within a person's energy limits, with a specialist team.
- Small trials: self-paced aquatic exercise improved 6-minute walk by 13.7% without adverse events (Australian RCT, Broadbent 2025, n=32).
Symptoms
- Orthostatic intolerance: fluids, salt, compression, then fludrocortisone, low-dose beta-blockers, ivabradine or pyridostigmine (Bateman 2021, consensus). Fludrocortisone RCT: β₯15-point wellness gain 14% vs 10% placebo, p=0.76 (Rowe 2001, n=100).
- Pyridostigmine: single 60 mg dose raised peak VO2 by 13.3 vs β40.2 mL/min on invasive CPET (Joseph 2022, n=45). Physiology only; no symptom outcome.
- Sleep and pain: sleep hygiene first; low-dose amitriptyline or doxepin, trazodone, mirtazapine; duloxetine, pregabalin (consensus; no ME/CFS RCTs). Start low: NICE suggests lower doses because of drug sensitivity.
- Cognition: methylphenidate beat placebo but only 17% were fatigue responders (Blockmans 2006, crossover n=60); lisdexamfetamine improved executive function (Young 2013, n=26).
- Practical support: work and school adjustments, mobility aids, carer support, NDIS and Disability Support Pension applications (the NHMRC CEO flagged reported exclusions to the minister in 2019).
Severe and very severe ME/CFS
- Environment: hypersensitivity to light, sound, touch, movement, temperature and smells; low-stimulus room, careful touch (NICE 1.17).
- Hospital: minimise PEM during transfers, single room where possible, dim light, low noise, stable temperature.
- Nutrition: monitor for malnutrition; oral support or enteral feeding, and some people need tube feeding.
- Immobility: postural support and prevention of complications of long-term immobility (NICE 1.12).
Emerging treatments and trials
- Rintatolimod (Ampligen): placebo-adjusted exercise tolerance +21.3% (p=0.047; Strayer 2012, n=234). FDA declined approval in 2013; Argentina approved it for severe ME/CFS in 2016.
- Daratumumab: 6 of 10 responded in an open-label pilot; SF-36 physical function 25.9 to 55.0 (Fluge 2025). An RCT is needed.
- Rapamycin: 74% of completers reported improvement in an uncontrolled study (Ruan 2025, n=86).
- Low-dose naltrexone: widely used off-label; no completed ME/CFS RCT. A Canadian post-COVID RCT reportedly missed its primary fatigue end point (conference report, 2026); LIFT (LDN Β± pyridostigmine, target n=160) has a published protocol.
- Immunoadsorption: 70% responders in an open study of post-COVID ME/CFS (Stein 2024, n=20), but a sham-controlled trial reported no difference at 60 days (preliminary, 2026).
- BC007 (rovunaptabin): neutralises GPCR autoantibodies; a phase 2 long COVID trial (n=119) failed in 2024; no ME/CFS trial found.
- Australia: Griffith University (NCNED) reports TRPM3 ion-channel dysfunction in NK cells that appears restored in LDN users (lab studies, n=9); a clinical trial is flagged for 2026. NHMRC's 2019 targeted call funded $3.3 million across Griffith, Deakin and Melbourne.
- Failed so far: rituximab (RituxME, n=151: response 26.0% vs 35.1% placebo); IVIG (Vollmer-Conna 1997, Sydney, n=99: no benefit); valganciclovir (primary end point missed); cyclophosphamide (55% open-label response, too toxic outside trials).
Theoretical frontiers
Hypotheses, not recommendations.
Causes: theories
- Hypothesis: persistent infection or reactivation drives it. For: the illness follows EBV, Q fever, Ross River virus, H1N1 and SARS-CoV-2 at similar rates (Hickie 2006; Vernon 2025). Against: valganciclovir missed its primary end point (Montoya 2013); similar rates across very different pathogens suggest a host response rather than one bug. Test: tissue-based pathogen searches and antiviral RCTs stratified by reactivation markers.
- Hypothesis: autoimmunity. For: GPCR antibodies (Loebel 2016); female predominance; immune-response genes in DecodeME. Against: RituxME negative; assay validity doubts (Hall 2022). Test: IgG passive-transfer studies in ME/CFS (done so far only in long COVID) and better assays.
- Hypothesis: an energy-metabolism block. For: hypometabolic profile (Naviaux 2016) and impaired PDH (Fluge 2016); day-2 CPET decline. Against: small, varied cohorts; Mancini 2026 found no day-2 change. Test: muscle biopsy and magnetic resonance spectroscopy before and after exertion.
- Hypothesis: impaired brain perfusion and autonomic control. For: 26% vs 7% cerebral blood flow fall on tilt (van Campen 2020). Against: NIH study found no tilt differences. Test: blinded multi-site tilt with CBF and symptom tracking.
- Hypothesis: exhausted T cells after chronic antigen exposure. For: CD8 exhaustion signatures (Iu 2024), CSF PD-1+ CD8 T cells (Walitt 2024). Against: small samples, sex-specific findings. Test: longitudinal immune profiling from acute infection onward.
- Hypothesis: inherited susceptibility. For: RR 2.70 in first-degree relatives; 8 GWAS loci. Against: modest effect sizes; European ancestry only; not yet peer-reviewed. Test: replication in diverse cohorts and functional studies of the loci.
Prevention: theoretical options
- Hypothesis: rest early after infection prevents chronicity. For: acute illness severity predicts outcome (Hickie 2006). Against: no trials. Test: RCT of early graded return vs paced return after glandular fever.
- Hypothesis: vaccination reduces cases. For: H1N1 infection HR 2.04 vs vaccine HR 0.97 (Magnus 2015). Against: indirect. Test: cohort data in EBV vaccine trials as they arrive.
- Hypothesis: early antivirals cut post-COVID ME/CFS. For: a defined trigger with 4.5% incidence. Against: no ME/CFS outcome data. Test: RECOVER-style antiviral trials with IOM criteria as an end point.
- Hypothesis: screening high-risk infections for PEM catches cases early. For: the Dubbo time course (27% at 3 months, 9% at 12). Against: no evidence that early detection changes outcome. Test: cluster-randomised GP follow-up after severe glandular fever.
Treatment: theoretical options
- Hypothesis: plasma-cell targeting works where rituximab failed. For: daratumumab pilot (6 of 10). Against: open-label, tiny. Test: placebo-controlled daratumumab RCT.
- Hypothesis: GPCR antibody removal helps a subgroup. For: open immunoadsorption responses (Stein 2024). Against: sham-controlled data negative; BC007 failed in long COVID. Test: trials enriched for antibody-positive patients.
- Hypothesis: TRPM3 restoration with LDN. For: Griffith lab data. Against: no completed RCT; post-COVID LDN trial reportedly negative. Test: LIFT and Griffith trials.
- Hypothesis: improving cardiac preload improves exercise capacity. For: pyridostigmine raised peak VO2 (Joseph 2022). Against: single dose, no symptom end point. Test: LIFT and longer RCTs with PEM outcomes.
- Hypothesis: mTOR inhibition restores autophagy. For: rapamycin cohort (Ruan 2025). Against: uncontrolled. Test: placebo-controlled RCT.
Gaps and open questions
- No biomarker: every candidate (NK function, CPET, antibodies, metabolites) lacks validation across sites.
- Case definitions: older trials used Fukuda or Oxford criteria, which don't require PEM.
- Outcome measures: unblinded self-report drove the PACE and GET debate; objective activity end points are rarely used.
- Severe ME/CFS: almost no trials include housebound or bedbound people.
- Australia: prevalence rests on old data; the new NHMRC guideline isn't due for public consultation until late 2027.
- Equity: DecodeME is European-ancestry; Indigenous, rural and low-income data are scarce, yet US prevalence is highest in non-metro and low-income groups.
Prognosis and quality of life
- Adults: median full recovery 5% (range 0β31%), improvement 39.5% (Cairns and Hotopf 2005, 14 studies).
- Young people: 38% recovered by 5 years and 68% by 10 years; 5% remained very unwell (Melbourne, Rowe 2019, n=784).
- Recent onset: 4 of 17 NIH participants (ill <5 years) recovered within 4 years (Walitt 2024).
- Quality of life: EQ-5D 0.47 vs 0.85 for the population, the lowest of 20 conditions compared (Falk Hvidberg 2015, Denmark).
- Mortality: all-cause SMR 1.14 (not significant) but suicide SMR 6.85 (Roberts 2016, n=2,147). Ask about mood and hope.
Weird trivia
- The staff got sick, not the patients: the 1955 Royal Free outbreak hit about 292 staff but only 12 inpatients.
- "Myalgia nervosa": the name McEvedy and Beard proposed in 1970 to replace "benign myalgic encephalomyelitis".
- Headline habits: early media called it "Raggedy Ann syndrome"; only 4 of 214 US newspaper headlines (1987β2013) used "yuppie flu", but the label stuck (Siegel 2018).
- Argentina first: rintatolimod's first approval anywhere was in Argentina in 2016; the FDA still hasn't approved it.
- Three bugs, one illness: a virus (EBV), a bacterium (Coxiella burnetii, Q fever) and a mosquito-borne alphavirus (Ross River) produced similar post-infective fatigue rates in Dubbo, NSW.
- Day 2 goes backwards: on repeat exercise testing, controls tend to match or beat day 1; people with ME/CFS often fall (Lim 2020 meta-analysis).
Guidelines
- NHMRC ME/CFS Advisory Committee report to the CEO (2019)
- NHMRC CEO response: 2002 RACP guidance to be replaced (October 2019)
- NHMRC: Australian ME/CFS guideline development (consultation planned 2027)
- Emerge Australia: clinical guidelines position and GP resources
- House of Representatives long COVID inquiry: ME/CFS addendum (2023)
- NICE NG206: ME/CFS diagnosis and management (2021)
- Institute of Medicine. Beyond ME/CFS: redefining an illness (2015)
- CDC: IOM 2015 diagnostic criteria for clinicians
- Bateman L et al. ME/CFS: essentials of diagnosis and management. Mayo Clin Proc 2021 (US ME/CFS Clinician Coalition)
- Carruthers BM et al. ME: International Consensus Criteria. J Intern Med 2011
Key trials
- PACE (White 2011): CBT, GET, adaptive pacing vs specialist care, n=641.
- RituxME (Fluge 2019): rituximab vs placebo, n=151, negative.
- Strayer 2012: rintatolimod, n=234.
- Rowe 2001: fludrocortisone, n=100, negative.
- Vollmer-Conna 1997: IVIG, n=99, negative.
- Dubbo cohort (Hickie 2006): post-infective fatigue, n=253.
- RECOVER-Adult (Vernon 2025): ME/CFS after COVID-19, n=13,224.
- LIFT (ongoing): LDN Β± pyridostigmine, target n=160.
Sources
- Fukuda K et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994
- Holmes GP et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988
- Carruthers BM et al. ME/CFS: Canadian clinical case definition. J Chronic Fatigue Syndr 2003
- Sigurdsson B et al. A disease epidemic in Iceland simulating poliomyelitis. Am J Hyg 1950
- Pellew RA, Miles JA. Further investigations on a disease resembling poliomyelitis seen in Adelaide. Med J Aust 1955
- McEvedy CP. Royal Free epidemic: DM thesis, University of Oxford
- McEvedy CP, Beard AW. Royal Free epidemic of 1955: a reconsideration. BMJ 1970
- McEvedy CP, Beard AW. Concept of benign myalgic encephalomyelitis. BMJ 1970
- Acheson ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med 1959
- ME Association. Dr Betty Dowsett (1920β2012), obituary
- CDC. Chronic fatigue possibly related to Epstein-Barr virus: Nevada. MMWR 1986
- Nakatomi Y et al. Neuroinflammation in patients with CFS/ME: an 11C-(R)-PK11195 PET study. J Nucl Med 2014
- Raijmakers R et al. No signs of neuroinflammation in women with CFS or Q fever fatigue syndrome. Neurol Neuroimmunol Neuroinflamm 2022
- Chu L et al. Deconstructing post-exertional malaise. PLoS One 2018
- Moore GE et al. Recovery from exercise in persons with ME/CFS. Medicina 2023
- Cotler J et al. A brief questionnaire to assess post-exertional malaise. Diagnostics 2018
- CDC. ME/CFS: approach to diagnosis
- Snell CR et al. Discriminative validity of metabolic and workload measurements for identifying people with CFS. Phys Ther 2013
- Keller B et al. Cardiopulmonary and metabolic responses during a 2-day CPET in ME/CFS. J Transl Med 2024
- Franklin JD, Graham M. Repeated maximal exercise tests of peak oxygen consumption in people with ME/CFS: meta-analysis. Fatigue 2022
- Lim EJ et al. Two-day CPET in ME/CFS: systematic review and meta-analysis. J Clin Med 2020
- Mancini D et al. Two-day CPET in ME/CFS. Front Physiol 2026
- van Campen CLMC et al. Cerebral blood flow is reduced in ME/CFS patients during head-up tilt testing. Clin Neurophysiol Pract 2020
- Walitt B et al. Deep phenotyping of post-infectious ME/CFS. Nat Commun 2024
- Kirvin-Quamme A et al. Unwilling or unable? Front Psychol 2025
- DecodeME Collaboration. Initial findings from the DecodeME genome-wide association study. medRxiv 2025 (preprint)
- Albright F et al. Evidence for a heritable predisposition to CFS. BMC Neurol 2011
- Baraniuk JN et al. NK cell cytotoxicity in ME/CFS: meta-analysis. Front Immunol 2024
- Iu DS et al. Transcriptional reprogramming primes CD8+ T cells toward exhaustion in ME/CFS. PNAS 2024
- Loebel M et al. Antibodies to Ξ² adrenergic and muscarinic cholinergic receptors in CFS. Brain Behav Immun 2016
- Hall J et al. Detection of G protein-coupled receptor autoantibodies in POTS. Circulation 2022
- Naviaux RK et al. Metabolic features of chronic fatigue syndrome. PNAS 2016
- Fluge Γ et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS. JCI Insight 2016
- Xiong R et al. Multi-omics of ME/CFS (BioMapAI). Nat Med 2025
- Lim EJ et al. Systematic review and meta-analysis of the prevalence of CFS/ME. J Transl Med 2020
- Vahratian A et al. ME/CFS in adults: United States, 2021β2022. NCHS Data Brief 488, 2023
- Bakken IJ et al. Two age peaks in the incidence of CFS/ME: Norway. BMC Med 2014
- CDC Grand Rounds: chronic fatigue syndrome. MMWR 2016
- Prevalence of ME/CFS in Australian primary care (MedicineInsight). BMC Public Health 2022
- Emerge Australia. Estimated 250,000 Australians (2024)
- Close S et al. The economic impacts of ME/CFS in an Australian cohort. Front Public Health 2020
- Hickie I et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006
- Katz BZ et al. CFS after infectious mononucleosis in adolescents. Pediatrics 2009
- Vernon SD et al. Incidence and prevalence of post-COVID-19 ME/CFS (RECOVER-Adult). J Gen Intern Med 2025
- Kedor C et al. A prospective observational study of post-COVID-19 CFS. Nat Commun 2022
- Magnus P et al. Chronic fatigue syndrome/ME is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 2015
- Rajabi et al. IBS in ME/CFS: meta-analysis. Front Med 2026
- Mudie K et al. Hypermobility in ME/CFS (You + ME registry). Front Neurol 2024
- Rohrhofer J et al. Mast cell activation in ME/CFS. Diagnostics 2025
- Maeve Boothby O'Neill: Prevention of Future Deaths report. Courts and Tribunals Judiciary 2024
- White PD et al. Comparison of adaptive pacing therapy, CBT, GET and specialist medical care (PACE). Lancet 2011
- Wilshire CE et al. Rethinking the treatment of CFS: a reanalysis of the PACE trial. BMC Psychol 2018
- Larun L et al. Exercise therapy for CFS. Cochrane Database Syst Rev (reissued 2024)
- NICE NG206 evidence review G: non-pharmacological management
- Geraghty K et al. Patients' experiences of CBT, GET and pacing: survey analysis. J Health Psychol 2019
- Broadbent S et al. Self-paced aquatic exercise in ME/CFS: RCT. Eur J Appl Physiol 2025
- Rowe PC et al. Fludrocortisone acetate to treat neurally mediated hypotension in CFS. JAMA 2001
- Joseph P et al. Pyridostigmine and exercise capacity in ME/CFS. Chest 2022
- Blockmans D et al. Methylphenidate in CFS: crossover RCT. Am J Med 2006
- Young JL. Lisdexamfetamine in CFS with executive dysfunction. Psychiatry Res 2013
- Fluge Γ et al. B-lymphocyte depletion in ME/CFS (RituxME). Ann Intern Med 2019
- Vollmer-Conna U et al. Intravenous immunoglobulin is ineffective in CFS. Am J Med 1997
- Montoya JG et al. Valganciclovir in CFS: RCT. J Med Virol 2013
- Rekeland IG et al. Cyclophosphamide in ME/CFS (CycloME). Front Med 2020
- Strayer DR et al. Rintatolimod in CFS/ME: RCT. PLoS One 2012
- FDA complete response letter for Ampligen (2013)
- Ampligen approved in Argentina (2016)
- Fluge Γ et al. Daratumumab in ME/CFS: open-label pilot. Front Med 2025
- Ruan BT et al. Rapamycin in ME/CFS. J Transl Med 2025
- LDN for post-COVID fatigue: RCT protocol. BMJ Open 2024
- LIFT trial protocol: LDN and pyridostigmine. Trials 2026
- The Sick Times. International ME/CFS conference roundup (May 2026)
- Stein E et al. Immunoadsorption in post-COVID ME/CFS. Lancet Reg Health Eur 2024
- The Sick Times. Berlin Cures' failed long COVID trial (2025)
- Cabanas H et al. Naltrexone restores TRPM3 function in NK cells of ME/CFS patients. Front Immunol 2021
- NHMRC ME/CFS targeted call: funding outcomes
- Cairns R, Hotopf M. A systematic review describing the prognosis of CFS. Occup Med 2005
- Rowe KS. Long term follow up of young people with CFS attending a paediatric outpatient service. Front Pediatr 2019
- Falk Hvidberg M et al. The health-related quality of life for patients with ME/CFS. PLoS One 2015
- Roberts E et al. Mortality of people with CFS: a retrospective cohort study. Lancet 2016
- Siegel Z et al. Media framing of CFS in US newspapers. Chronic Illn 2018
Information only. Check product information, PBS criteria and current Australian guidelines before prescribing. No medicine is TGA-approved specifically for ME/CFS, and the medicines above are used off-label.
maladywise.com/deep-dives/me-cfs/